1 + 2
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft
Conditions
Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft
Trial Timeline
May 1, 2010 → Apr 1, 2013
NCT ID
NCT01056822About 1 + 2
1 + 2 is a approved stage product being developed by Novartis for Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft. The current trial status is completed. This product is registered under clinical trial identifier NCT01056822. Target conditions include Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01056822 | Approved | Completed |